B
Belharra Therapeutics
Belharra Therapeutics is the next generation of small molecule discovery - a company founded by the pioneers of the field of chemical biology
About Belharra Therapeutics
Belharra is a biotech startup that operates in the pharmaceutical industry, specifically in the area of drug discovery. The company's primary focus is on the development of drugs that target proteins previously considered "undruggable". Traditional drug discovery methods often focus on specific targets within a controlled environment, but Belharra's innovative approach expands these possibilities. Their platform uses probes to explore the native environment of a cell, without the need for predefined bioassays, a laboratory test used to assess the effects of a substance on a living organism.
Belharra's business model is centered around the research and development of these new drugs. The company's revenue is likely generated through partnerships with larger pharmaceutical companies, licensing agreements, and potentially, the sale of their drugs once approved and commercialized. Their clients would primarily be other businesses in the pharmaceutical industry, healthcare providers, and patients suffering from diseases currently considered untreatable.
Belharra's vision is to change the human experience by creating a world where no disease is untreatable. They are currently building a team of innovative scientists who have the knowledge and determination to navigate the challenging waters of drug discovery.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- San Diego, United States
- Employees
- 38
- Open positions
- None listed
- Dealroom signal
- 66.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Tech for Biotech and Pharma, Biotech and Pharma, Techbio, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jan 2023 | $80M | $320M | Roche | ↗ |
| SERIES AOther financing | Jan 2023 | $50M | $200M | Versant Ventures | ↗ |
Growth signals
Latest recorded traffic for Belharra Therapeutics is 1.9K monthly website visits, down 24% over the last three months. Belharra Therapeutics's team declined 2.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Roche
Versant Ventures
Other known investors1 additional known investor
Scripps Translational Science Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Belharra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Belharra Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







